Viridian Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
43.17
|
|
Average Rating
|
4.67
|
|
# Strong Buys
|
8
|
|
# Buys
|
4
|
|
# Holds
|
0
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-1.02
|
-0.86
|
0.16
|
15.69%
|
|
2022-06-30
|
-0.90
|
-1.06
|
-0.16
|
-17.78%
|
|
2022-03-31
|
-1.08
|
-0.98
|
0.10
|
9.26%
|
|
2021-12-31
|
-0.90
|
-1.32
|
-0.42
|
-46.67%
|
|
2021-09-30
|
-1.47
|
-1.25
|
0.22
|
14.97%
|
|
2021-06-30
|
-1.52
|
-2.21
|
-0.69
|
-45.39%
|
|
2021-03-31
|
-0.76
|
-2.91
|
-2.15
|
-282.89%
|
|
2020-12-31
|
-0.61
|
-5.31
|
-4.70
|
-770.49%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-2.90
|
|
2021-12-31
|
-7.69
|
|
2020-12-31
|
-11.31
|
|
2019-12-31
|
-20.10
|
|
2018-12-31
|
-5.71
|
|
2017-12-31
|
-1.50
|
|
2016-12-31
|
-14.25
|
|
2015-12-31
|
-21.75
|
|
2014-12-31
|
-281.14
|